Evidence map›Paper›PMID 32489443›Full record

ArticleAnnals of thoracic medicine

A comparison between warfarin and apixaban: A patient's perspective.

Abdullah U Althemery, Abdullah A Alfaifi, Abdulrahman Alturaiki, Maha A L Ammari, Khizra Sultana, Leanne Lai

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of thoracic medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Abdullah U AlthemeryDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Abdullah A AlfaifiDepartment of Clinical Pharmacy, College of Pharmacy, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Abdulrahman AlturaikiDepartment of Pharmaceutical Care, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
Maha A L AmmariDepartment of Pharmaceutical Care, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
Khizra SultanaDepartment of Pharmaceutical Care, Ministry of the National Guard - Health Affairs, Riyadh, Saudi Arabia.
Leanne LaiSociobehavioral Administrative Pharmacy, Nova Southeastern University, College of Pharmacy 3200 S. University Drive, Ft. Lauderdale, FL, USA.
National Guard Health Affairs · SAPrince Sattam Bin Abdulaziz University · SAKing Abdullah International Medical Research Center · SANova Southeastern University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNovel oral anticoagulants (NOACs) were developed as alternatives to warfarin. However, the patients' preference regarding warfarin or the NOACs has not been established. Quality-of-life (QOL) surveys are a well-established method for determining the patients' preference for a treatment route.

aimsThis study compared the patients' perspectives on treatment with warfarin versus apixaban using the QOL measures. SETTINGS AND

designThis cross-sectional study was conducted in 2019 for patients treated with either warfarin or apixaban at King Abdulaziz Medical City, Riyadh, Kingdom of Saudi Arabia.

methodsWe used a series of descriptive statistics to examine the differences in sociodemographic characteristics among patients. A propensity score-matching approach was employed to reduce the effect of confounding variables that often influence treatment selection. Greedy matching approach was used to analyze the QOL.

resultsA total of 388 patients were identified, of which 124 were matched between the two groups (62 patients in each group). Most of the patients were female, married, below the sufficiency level, educated, and nonsmokers. The patients using warfarin had a significantly better health state (

conclusionsFuture studies should explore why patients using apixaban showed lower QOL scores and improve health-care providers' awareness of these issues.

Indexed as

ApixabanEuroQoLoral anticoagulantspatient-reported outcomespropensity score matchingwarfarin

Identifiers

PMID32489443
PMCPMC7259398
OpenAlexW3014695991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.